Matches in Wikidata for { <http://www.wikidata.org/entity/Q66063707> ?p ?o ?g. }
Showing items 1 to 41 of
41
with 100 items per page.
- Q66063707 description "clinical trial" @default.
- Q66063707 description "ensayu clínicu" @default.
- Q66063707 description "klinisch onderzoek" @default.
- Q66063707 description "клінічне випробування" @default.
- Q66063707 name "PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors" @default.
- Q66063707 name "PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors" @default.
- Q66063707 type Item @default.
- Q66063707 label "PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors" @default.
- Q66063707 label "PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors" @default.
- Q66063707 prefLabel "PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors" @default.
- Q66063707 prefLabel "PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors" @default.
- Q66063707 P1132 Q66063707-6550318D-D4BC-4DD8-A5E8-4FE3C6011356 @default.
- Q66063707 P1476 Q66063707-DA4F6FF8-6597-4CBC-AACE-3C8034880AC6 @default.
- Q66063707 P17 Q66063707-3933089D-3892-45E6-96E7-E6C11EE8E90F @default.
- Q66063707 P2899 Q66063707-37A415DC-4909-4C38-A4CD-545C95315E4E @default.
- Q66063707 P3098 Q66063707-36782CAA-189D-4732-9161-A9C300DDD592 @default.
- Q66063707 P31 Q66063707-29AA49AA-B871-4C47-BB6B-7698E16824E1 @default.
- Q66063707 P580 Q66063707-3E6954B1-AC31-4A91-8435-51D2B7632580 @default.
- Q66063707 P582 Q66063707-E1471D6A-5CCE-4FAA-8B25-72614283372A @default.
- Q66063707 P6099 Q66063707-397872C7-DDCF-4679-AED1-10D0ED5B4CFA @default.
- Q66063707 P6153 Q66063707-2209E3FA-C898-423A-B730-0EDD15172EDF @default.
- Q66063707 P6153 Q66063707-2C6AEFA4-EC38-4B38-912C-15A55B3F5D33 @default.
- Q66063707 P6153 Q66063707-5C2E9A51-3125-4D9C-AAA3-F383ECF31B9F @default.
- Q66063707 P6153 Q66063707-5FBF4DB4-BC29-42A5-9740-A33B9B97EDEC @default.
- Q66063707 P6153 Q66063707-96FACDD6-3C28-4130-B747-D8DE7ECDE7FB @default.
- Q66063707 P8363 Q66063707-EA2C7625-A58E-49F1-B5A4-DB0C97834E69 @default.
- Q66063707 P1132 "+160" @default.
- Q66063707 P1476 "A Phase 2, Open-Label, Multi-cohort Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors" @default.
- Q66063707 P17 Q30 @default.
- Q66063707 P2899 "+18" @default.
- Q66063707 P3098 "NCT03993379" @default.
- Q66063707 P31 Q30612 @default.
- Q66063707 P580 "2019-07-01T00:00:00Z" @default.
- Q66063707 P582 "2021-01-01T00:00:00Z" @default.
- Q66063707 P6099 Q42824440 @default.
- Q66063707 P6153 Q1159198 @default.
- Q66063707 P6153 Q131252 @default.
- Q66063707 P6153 Q4403855 @default.
- Q66063707 P6153 Q4803501 @default.
- Q66063707 P6153 Q5123723 @default.
- Q66063707 P8363 Q78089383 @default.